Nike's 72.3% Resale Share Is Encouraging, but It Is Not Revenue

Citi-tracked resale data showed Nike and Jordan gaining share in September. The signal suggests stronger secondary-market demand, but Nike's own quarterly revenue and inventory trends remain the more important evidence.
Nike and Jordan products accounted for 72.3% of the tracked U.S. sneaker resale market in September, according to data reported by Citi, an increase of 63 basis points from the prior month.
That is a useful demand signal, especially because Jordan led the gains. A healthy secondary market can indicate cultural relevance, product scarcity and consumer willingness to pay. It can also help Nike manage launches and wholesale allocation.
Resale share is not the same as Nike revenue. Transactions occur between buyers and sellers after the original sale, and high prices may reflect deliberately limited supply rather than broad demand. The dataset's marketplace coverage and methodology also matter, so one month's movement should not be treated as a complete view of the brand.
Nike's own fiscal first-quarter results were more mixed. Revenue fell 4% to $11.2 billion, Nike Direct revenue declined to $4.1 billion from $4.5 billion, and inventory rose 5% from May to $7.8 billion. Gross margin improved 60 basis points to 42.8%, helped by lower warehousing and logistics costs. Management said work on Nike Sportswear, Jordan Brand and Greater China would extend beyond fiscal 2027.
The contrast is the real story. Resale data suggests continued heat in selected products, while company results show a broader portfolio still in transition. Investors should look for whether stronger resale demand translates into full-price sell-through, lower promotions and healthier inventory.
Nike benefits if Jordan momentum expands beyond scarce releases. Until that appears in reported revenue and margins, the 72.3% share is supporting evidence, not a turnaround verdict.
Related News
FICO's 16% Rebound Did Not Remove Its Mortgage Pricing Risk
FICO rebounded without a confirmed new catalyst after a steep selloff. FHFA's unified pricing approach for FICO and VantageScore still threatens the mortgage-score economics behind recent growth.
Sunrun's New Low Puts Cash Generation Ahead of Growth
Sunrun shares approached a 52-week low before earnings. Battery attachment is rising, but weaker subscriber economics and lower cash-generation guidance make the next report an execution test.
Lumentum's 25% Slide Tests a Valuation Built on Scarcity
Lumentum fell 25% in five sessions even as AI-related optical demand remained strong. The selloff exposed how much future growth was already embedded in a price-to-sales multiple above 20.
Amazon's $350 Bull Case Requires AWS Margins to Beat Capex
Morgan Stanley's higher Amazon target assumes faster AWS growth and expanding cloud margins despite enormous capital spending. Amazon's October 29 results will test whether profit is keeping pace.
Eli Lilly's Growth Is Powerful, but Pricing Is the Real Margin Test
Eli Lilly's second-quarter revenue rose 48% to $23 billion as Mounjaro and Zepbound volumes expanded. Retatrutide strengthens the pipeline, while lower realized prices and manufacturing commitments define the next investor test.
Micron Funds U.S. Indium Capacity to Reduce a Quiet Supply Risk
Micron is funding an Indium Corporation expansion in Rome, New York, and plans a long-term supply agreement. The undisclosed investment targets a concentrated materials bottleneck rather than near-term chip output.















Latest comments